Characteristics of Dopaminergic Neurotoxicity Produced by MPTP and Methamphetamine a

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Annals of the New York Academy of Sciences

• Publication date

  1992-05-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1111/j.1749-6632.1992.tb24542.xPMID 1637048
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice.

  1991cited by this paper
• Competitive and noncompetitive antagonists at N-methyl-D-aspartate receptors protect against methamphetamine-induced dopaminergic damage in mice.

  1990cited by this paper
• 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia.

  1990cited by this paper
• Potentiation by the Tetraphenylboron Anion of the Effects of 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine and Its Pyridinium Metabolite

  1990cited by this paper
• Structure-activity study of the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. I. Evaluation of the biological activity of MPTP analogs.

  1989cited by this paper
• Structure-activity study of the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. II. Evaluation of the biological activity of the pyridinium metabolites formed from the monoamine oxidase-catalyzed oxidation of MPTP analogs.

  1989cited by this paper
• Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity.

  1989cited by this paper
• Deprenyl as prophylaxis against Parkinson's disease?

  1988cited by this paper
• 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine Metabolism and l‐Methyl‐4‐Phenylpyridinium Uptake in Dissociated Cell Cultures from the Embryonic Mesencephalon

  1988cited by this paper
• Importance of monoamine oxidase A in the bioactivation of neurotoxic analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  1988cited by this paper
• Neuroprotective effects of adenosine.

  1988cited by this paper
• Neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and methamphetamine in several strains of mice.

  1988cited by this paper
• Adenosine and dopamine function in the CNS

  1987cited by this paper
• Characteristics of 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the mouse.

  1987cited by this paper
• Evaluation of the Biological Activity of Several Analogs of the Dopaminergic Neurotoxin 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine

  1987cited by this paper
• Astrocytes convert the parkinsonism inducing neurotoxin, MPTP, to its active metabolite, MPP+.

  1987cited by this paper
• Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice.

  1987cited by this paper
• 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) cause rapid ATP depletion in isolated hepatocytes.

  1986cited by this paper
• The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice.

  1986cited by this paper
• Brain dialysis in conscious rats reveals an instantaneous massive release of striatal dopamine in response to MPP+.

  1986cited by this paper
• Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria.

  1986cited by this paper
• Roles of D1 and D2 dopamine receptor subtypes in mediating the methamphetamine-induced changes in monoamine systems.

  1986cited by this paper
• Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.

  1985cited by this paper
• Differential neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in Swiss-Webster mice from different sources.

  1985cited by this paper
• Role of dopamine in the neurotoxic effects of methamphetamine.

  1985cited by this paper
• Studies on the molecular mechanism of bioactivation of the selective nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  1985cited by this paper
• Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity.

  1985cited by this paper
• Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors

  1984cited by this paper
• Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice.

  1984cited by this paper
• Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in rat, guinea pig, and monkey.

  1984cited by this paper
• Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism

  1984cited by this paper
• Further studies on the long-term depletion of striatal dopamine in iprindole-treated rats by amphetamine.

  1982cited by this paper
• Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons.

  1982cited by this paper
• Influence of methamphetamine and neuroleptic drugs on tyrosine hydroxylase activity.

  1974cited by this paper

• Standardization and validation of novel ex-vivo method for mitochondrial bioenergetics using mitochondrial modulators.

  2022cites this paper
• MPTP Neurotoxicity: Actions, Mechanisms, and Animal Modeling of Parkinson’s Disease

  2021cites this paper
• Neuropsychological Aspects of Methamphetamine Use Disorders and Human Immunodeficiency Virus Disease

  2016cites this paper
• Effects of aging on glutamate neurotransmission in the substantia nigra of Gdnf heterozygous mice.

  2015cites this paper
• Running wheel exercise before a binge regimen of methamphetamine does not protect against striatal dopaminergic damage

  2014cites this paper
• MPTP Neurotoxicity: Actions, Mechanisms, and Animal Modelling of Parkinson’s Disease

  2014cites this paper
• Running wheel exercise ameliorates methamphetamine‐induced damage to dopamine and serotonin terminals

  2012cites this paper
• A dual-hit animal model for age-related parkinsonism.

  2010cites this paper
• 9-Methyl-β-carboline has restorative effects in an animal model of Parkinson’s disease

  2010cites this paper
• 9-Methyl-beta-carboline has restorative effects in an animal model of Parkinson's disease.

  2010cites this paper
• Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: current status of dopamine system vulnerability in NeuroAIDS.

  2008cites this paper
• Long-Term Consequences of Methamphetamine Exposure in Young Adults Are Exacerbated in Glial Cell Line-Derived Neurotrophic Factor Heterozygous Mice

  2007influential citation
• Inclusion Dynamics in PC12 is Comparable Between Amphetamines and MPTP

  2006cites this paper
• Ubiquitin-immunoreactive structures in the midbrain of methamphetamine abusers.

  2005influential citation
• Influence of paraquat on dopaminergic transporter in the rat brain.

  2005cites this paper
• Neurotoxic regimens of methamphetamine induce persistent expression of phospho‐c‐Jun in somatosensory cortex and substantia nigra

  2005cites this paper
• Minocycline enhances MPTP toxicity to dopaminergic neurons

  2003influential citation
• Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice.

  2003cites this paper
• Role of α-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice

  2003cites this paper
• Molecular and Cellular Events Regulating Dopamine Neuron Survival

  2002cites this paper
• Molecular Basis for Interactions of HIV and Drugs of Abuse

  2002cites this paper
• Dose-dependent protective effects of apomorphine against methamphetamine-induced nigrostriatal damage.

  2001cites this paper
• Methamphetamine toxicity in mice is potentiated by exposure to loud music

  2001cites this paper
• Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases.

  2000cites this paper
• The role of the locus coeruleus in the development of Parkinson's disease.

  2000cites this paper
• Repeated administration of methamphetamine damages cells in the somatosensory cortex: Overlap with cytochrome oxidase‐rich barrels

  2000cites this paper
• Advances in Research on Neurodegeneration

  1999cites this paper
• Neural transplantation in animal models of multiple system atrophy: a review.

  1999cites this paper
• Effects of Repeated High-Dose Methamphetamine on Local Cerebral Glucose Utilization in Rats

  1999cites this paper
• Agonists of A1 and A2A adenosine receptors attenuate methamphetamine-induced overflow of dopamine in rat striatum.

  1998cites this paper
• Glutamatergic involvement in psychomotor stimulant action.

  1998cites this paper
• Gene therapeutic strategies for neuroprotection: implications for Parkinson's disease.

  1997cites this paper
• Species differences in the role of excitatory amino acids in experimental parkinsonism.

  1997cites this paper
• Damage to dopaminergic nerve terminals in mice by combined treatment of intrastriatal malonate with systemic methamphetamine or MPTP.

  1996cites this paper
• Treatment of mice with methamphetamine produces cell loss in the substantia nigra.

  1996cites this paper
• Benzamide, an inhibitor of poly(ADP-ribose) polymerase, attenuates methamphetamine-induced dopamine neurotoxicity in the C57B1/6N mouse.

  1996cites this paper
• Methamphetamine and dopamine neurotoxicity: differential effects of agents interfering with glutamatergic transmission.

  1995cites this paper
• The role of N-methyl-D-aspartate receptors in dopaminergic neuropathology produced by the amphetamines.

  1995cites this paper
• Estimating Hydroxyl Radical Content in Rat Brain Using Systemic and Intraventricular Salicylate: Impact of Methamphetamine

  1995cites this paper
• The role of excitatory amino acids in experimental models of Parkinson's disease

  1994cites this paper